Sanofi is all set to hit the ground running if, as expected, the US Food and Drug Administration, gives the green light in the next couple of months to the mega blockbuster Dupixent as the first biologic for chronic obstructive pulmonary disease (COPD).
Dupixent (dupilumab), developed with Regeneron, is a huge seller and generated revenues of €10.72bn in 2023 for Sanofi from a range of type 2 inflammatory-driven conditions, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis and prurigo nodularis